Are your supplements damaging your kidneys? Don't be fooled by the natural label—many common supplements can actually harm ...

Spironolactone does not reduce the rate of cardiovascular death or heart failure in patients undergoing maintenance dialysis.

Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in ...

The following is a summary of “Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE database,” published in the April 2025 ...

A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...

When you have too much potassium in your blood, it’s called hyperkalemia. There are two types of hyperkalemia: acute and chronic. Acute hyperkalemia is a sudden, severe rise in blood potassium ...

The investigational technology uses Lead I ECG data to alert patients and clinicians of moderate to severe episodes of hyperkalemia (excess potassium in the blood) that can lead to sudden cardiac ...

Hyperkalemia, or high potassium, is a common and potentially life-threatening complication of kidney disease that can cause muscle cramps, nausea, lethargy, trouble breathing, irregular heartbeats ...

"This milestone reflects our shared commitment to addressing the needs of over 300,000 patients in Japan affected by hyperkalemia 6, particularly those with chronic kidney disease or heart failure.

More information: Tao Huang et al, GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed ...